Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04103840
Other study ID # IEC-08/2019-1270
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date August 27, 2019
Est. completion date December 1, 2022

Study information

Verified date March 2020
Source Postgraduate Institute of Medical Education and Research
Contact Madhumita Premkumar, DM
Phone 01722756344
Email drmadhumitap@gmail.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Chronic alcohol consumption is associated with intestinal bacterial dysbiosis, yet little is known about the role of intestinal fungi, or mycobiota in liver disease. Although the intestinal microbiome contains bacteria, fungi, and viruses, research in the field of liver disease has almost exclusively focused on the interaction between the host and gut bacteria. The fungal microbiota is an integral part of the gastrointestinal micro-ecosystem with up to 106 microorganisms per gram of faeces. Numerous interactions between fungi and bacteria and the complex immune response to gastrointestinal commensal or pathogenic fungi have been demonstrated in prior studies. Alcohol-dependent patients display a reduced intestinal fungal diversity and Candida overgrowth. Compared with healthy individuals and patients with non-alcohol-related cirrhosis, alcoholic cirrhosis patients also demonstrate systemic exposure and immune response to mycobiota. Thus, chronic alcohol consumption is associated with an altered mycobiota and translocation of fungal products. Manipulating the intestinal mycobiome might be an effective strategy for attenuating alcohol-related liver disease especially alcoholic hepatitis. In this study, we will attempt to find out the natural fungal mycobiome in Severe alcoholic hepatitis when compared with apparently healthy asymptomatic controls from their family. This will allow us to therapeutically modify the unbalanced gut microbiota and improve patient outcomes. Secondly, it will provide further insight as to why alcohol-associated hepatitis patients are particularly susceptible to fungal infections. In the age of frequent antibacterial drug therapy, the role of commensal and pathogenic fungi in the human gut has gained paramount importance.


Description:

The patients of severe alcohol-associated hepatitis admitted under Department of Hepatology, in Liver intensive Care Unit (LICU) Male or Female medical wards or coming to follow up in Liver clinic of Postgraduate Institute of Medical Education and Research, Chandigarh, India from will be screened for enrolment after ethical approval from the institute ethics committee. Both previously compensated and decompensated patients will be enrolled in this prospective observational pilot study. All patients will be followed up at 30 and 90 days from inclusion into the study.

Estimation of sample size Sample size will be estimated based on previous studies. This is a pilot prospective observational study. Based on currently available data from our centre on acute-on chronic liver failure, 22.5% of cirrhotics have suspected IFI, and up to 25% of SAH have suspicion for IFI, it is estimated that a total sample size of 60 patients would be required, with an effect size of 0.5, alpha 0.05, and power 0.85. Therefore, 80 patients will be required to enroll to account for 15% attrition. Hence, we propose to enroll 80 consecutive patients with SAH with 80 matched controls from their family starting from 15th August 2019.


Recruitment information / eligibility

Status Recruiting
Enrollment 160
Est. completion date December 1, 2022
Est. primary completion date October 1, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria:

- Severe Alcoholic Hepatitis

- Aged between 18 Years to 70 Years

- Either gender

- Study will also include age matched healthy controls from the patient's family

Exclusion Criteria:

1. Inability to obtain informed consent from patient or relatives.

2. Severe cardiopulmonary disease

3. Pregnancy

4. HIV infection

5. Recent abdominal surgery (with in last 6 months)

6. Patient on immunosuppressive drugs

7. Malignancies including Hepatocellular carcinoma

8. Gastrointestinal (GI bleed) in the last 4 weeks

9. Oral antibiotics or antifungals taken in last 2 weeks.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Testing stool mycobiota
Both cohorts of SAH and their family controls will be tested for fecal mycobiota

Locations

Country Name City State
India Postgraduate Institute of Medical Education and Research Chandigarh Choose Any State/Province

Sponsors (1)

Lead Sponsor Collaborator
Postgraduate Institute of Medical Education and Research

Country where clinical trial is conducted

India, 

Outcome

Type Measure Description Time frame Safety issue
Primary Survival Patients who survive till Day 28 and Day 90 at Day 28 and Day 90
Secondary Non-elective hospital admissions Number of hospital admissions will be documented 90 Days
Secondary Clinical and biochemical parameters will be compared at 0 and 90 days Change in biochemical parameters including liver function tests, renal function tests, ammonia etc. 90 days
Secondary Clinical events like decompensation in the form of new onset ascites, variceal bleed, renal dysfunction, hepatic encephalopathy, infections Number of decompensation events [ascites, variceal bleed, renal dysfunction, hepatic encephalopathy, infections] 90 days
See also
  Status Clinical Trial Phase
Completed NCT05407272 - Explore the Sharing Model Intervene to Improve the Knowledge, Attitudes, Service Intentions and Service Start-up Effects of the Eight Major Non-cancer Disease End-stage Caregivers on Well-being and Palliative Care N/A
Recruiting NCT05449873 - No-touch Radiofrequency Ablation for Recurrent Hepatocellular Carcinoma Using Triple Cooled-Wet Electrodes N/A
Recruiting NCT04660409 - Assessment of the Correlation Between Serum Levels of Adropin and Degree of Severity of Chronic Liver Disease N/A
Completed NCT05376826 - Effectiveness of Nurse-led Physical Therapy in Terms of Patient Competency, Patient Engagement and Physical Performance. N/A
Recruiting NCT06432582 - hepatomiR cACLD Study
Completed NCT05717569 - Different Regimens of Vitamin D in Treatment of Children With Chronic Liver Disease N/A
Not yet recruiting NCT05163132 - Shear-wave Elastography Diffuse Liver Disease
Completed NCT03562585 - Immunological Measurement of Aspartate/Alanine Aminotransferase
Not yet recruiting NCT06181448 - Real-World Validation of a Prognostic Prediction Model for Patients With Acute Exacerbations of Chronic Liver Disease
Not yet recruiting NCT04690972 - "Constitution of a Biological Collection to Establish Preclinical Translational Models for the Study of Tumors and Chronic Liver Diseases".
Not yet recruiting NCT06163001 - Role of Exercise in Chronic Liver Disease Patients Undergoing Liver Transplantation N/A